49.18 0.00 (0.00%)
After hours: 4:14PM EDT
|Bid||47.51 x 800|
|Ask||49.25 x 38500|
|Day's Range||48.83 - 49.43|
|52 Week Range||44.28 - 58.37|
|PE Ratio (TTM)||19.70|
|Forward Dividend & Yield||1.28 (2.65%)|
|1y Target Est||60.40|
Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.
Novo Nordisk of Denmark, the world’s largest manufacturer of diabetes medicines, has bought Ziylo, a small UK biotech company spun out of the University of Bristol, in an unusual deal that both parties said could eventually be worth more than $800m if a series of milestones are met. Novo Nordisk sees Ziylo’s technology as the path to success in a “key strategic area”: the development of “glucose responsive insulins” whose activity depends on the amount of sugar in the patient’s bloodstream. This control would prevent hypoglycaemia, caused by a dangerous fall in blood glucose level, which is the main risk associated with insulin therapy for diabetes.
Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018, a ~4% YoY (year-over-year) decline in local currencies.
This year, analysts expect GlaxoSmithKline’s (GSK) revenue to grow 0.4% YoY (year-over-year) to ~30.3 billion British pounds from ~30.2 billion pounds, and its income margin to narrow YoY to 17.9% from 18.1%. They expect it to report EPS of 110.75 pence.
In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.
Novo Nordisk’s (NVO) premix insulin segment witnessed a ~1% YoY (year-over-year) growth in local currencies in the first half of 2018 to 5.2 billion Danish kroner. That included revenues of 688 million Danish kroner, 856 million Danish kroner, 1.3 billion Danish kroner, and 1.9 billion Danish kroner in the United States, Europe, AAMEO (Africa, Asia, the Middle East, and Oceania), and China, respectively.
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.
In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.
Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.
Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.
On a per-share basis, the Bagsvaerd, Denmark-based company said it had profit of 68 cents. The drugmaker posted revenue of $4.39 billion in the period. Novo Nordisk shares have declined slightly more than ...
Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk, discusses the market reaction to earnings, drug prices in the U.S. and their M&A prospects. He speaks on "Bloomberg Markets: European ...
The Danish pharma group is facing intensifying competition over prices — particularly in the US — and while negotiations with pharmacy benefit managers and managed care organisations were progressing, it expected average prices after rebates “to be lower compared with the levels in 2018”. Lars Fruergaard Jorgensen, chief executive, said sales growth in the first half of 2018 had been driven by “solid performance of our key innovative products” — Saxenda for obesity and Victoza, Tresiba and Xultophy for diabetes.
Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31. The company is a global pharmaceuticals player with products and therapies across the specialty areas of oncology, immunology, vaccines, multiple sclerosis, rare disease disorders, neurology, cardiovascular diseases, diabetes, and infectious diseases. As of July 25, according to a recent Reuters survey, two of the five analysts covering SNY stock have given it a “strong buy” recommendation, and three have rated it a “hold.” There are no “sell” ratings.
As we’ve already seen, Novartis (NVS) reported a 7% growth in operating revenues to ~$13.16 billion in Q2 2018. That compares to revenues of ~$12.24 billion in Q2 2017.
Let's check out the Yahoo Finance charts of the day. Amazon (AMZN): Shares are up in early trade, at around .25%. Amazon is adding a curbside pickup option at Whole Foods for Prime members. Shoppers will be able to order milk, eggs and other groceries on the Prime Now app and park in reserved spaces where workers will place the items in their cars. Novo Nordisk (NVO): Shares down here at 5.34%. The Danish pharmaceutical company reported profit in line with forecasts for the second quarter, but the company said prices in the U.S, market would be lower next year. Tesla (TSLA): Shares down here, at around .68%. Tesla is on watch following Elon Musk's tweet Tuesday about possible plans to take the company private and reports of a $2 billion dollar investment in the Saudi Arabia investment fund. Members of the Tesla board said they have met "several times" to discuss Musk's desire to go private. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.
Aug.08 -- Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk, discusses the market reaction to earnings, drug prices in the U.S. and their M&A prospects. He speaks on "Bloomberg Markets: European Open."